These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 4082237)

  • 21. Theophylline. Pooled Michaelis-Menten parameters (Vmax and Km) and implications.
    Wagner JG
    Clin Pharmacokinet; 1985; 10(5):432-42. PubMed ID: 3899457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of modified Michaelis - Menten equations for determination of enzyme inducing and inhibiting drugs.
    Saganuwan SA
    BMC Pharmacol Toxicol; 2021 Oct; 22(1):57. PubMed ID: 34635182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Theoretical considerations in the calculation of bioavailability of drugs exhibiting Michaelis-Menten elimination kinetics.
    Rubin GM; Tozer TN
    J Pharmacokinet Biopharm; 1984 Aug; 12(4):437-50. PubMed ID: 6527233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of bioavailability on the calculated Michaelis-Menten parameters of phenytoin in children.
    Koren G; Brand N; MacLeod SM
    Ther Drug Monit; 1984; 6(1):11-4. PubMed ID: 6710554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Explicit solution of integrated 1 - exp equation for predicting accumulation and decline of concentrations for drugs obeying nonlinear saturation kinetics.
    Keller F; Hartmann B; Czock D
    Ther Drug Monit; 2009 Dec; 31(6):783-5. PubMed ID: 19881403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Michaelis-Menten from an In Vivo Perspective: Open Versus Closed Systems.
    Gabrielsson J; Peletier LA
    AAPS J; 2018 Sep; 20(6):102. PubMed ID: 30209711
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Population kinetic program for Michaelis-Menten elimination].
    Lü M; Zhou HW; Song JF
    Zhongguo Yao Li Xue Bao; 1990 Jan; 11(1):85-8. PubMed ID: 2403022
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A simple method for estimating half-life of drugs obeying Michaelis-Menten elimination kinetics].
    Ding Y; Huang DK; Luo JP
    Zhongguo Yao Li Xue Bao; 1995 Jan; 16(1):65-7. PubMed ID: 7771200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A nonlinear physiologic pharmacokinetic model: I. Steady-state.
    Wagner JG; Szpunar GJ; Ferry JJ
    J Pharmacokinet Biopharm; 1985 Feb; 13(1):73-92. PubMed ID: 4020623
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The steady-state Michaelis-Menten analysis of P-glycoprotein mediated transport through a confluent cell monolayer cannot predict the correct Michaelis constant Km.
    Bentz J; Tran TT; Polli JW; Ayrton A; Ellens H
    Pharm Res; 2005 Oct; 22(10):1667-77. PubMed ID: 16180124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. One-point feedback control method for phenytoin dosage adjustment.
    Yukawa E; Higuchi S; Aoyama T
    J Pharm Pharmacol; 1991 Jul; 43(7):499-503. PubMed ID: 1682464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simulation for population analysis of Michaelis-Menten elimination kinetics.
    Hashimoto Y; Koue T; Otsuki Y; Yasuhara M; Hori R; Inui K
    J Pharmacokinet Biopharm; 1995 Apr; 23(2):205-16. PubMed ID: 8719237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal phenytoin therapy: a new technique for individualizing dosage.
    Mullen PW
    Clin Pharmacol Ther; 1978 Feb; 23(2):228-32. PubMed ID: 620485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sensitivity analysis of the effect of bioavailability or dosage form content on mean steady state phenytoin concentration.
    Ludden TM; Allerheiligen SR; Browne TR; Koup JR
    Ther Drug Monit; 1991 Mar; 13(2):120-5. PubMed ID: 2053118
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of population pharmacokinetic parameters of phenytoin using the parallel Michaelis-Menten and first-order elimination model.
    Valodia PN; Seymour MA; McFadyen ML; Miller R; Folb PI
    Ther Drug Monit; 2000 Jun; 22(3):313-9. PubMed ID: 10850399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interindividual variation in the extent and rate of phenytoin accumulation.
    Levine M; Orr J; Chang T
    Ther Drug Monit; 1987 Jun; 9(2):171-6. PubMed ID: 3617156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic analysis of drug concentration data obtained during repetitive drug administration.
    Colburn WA; Gibaldi M
    J Pharm Sci; 1977 Apr; 66(4):530-3. PubMed ID: 856973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phenytoin dosage adjustment method using population clearance.
    Yukawa E; Higuchi S; Aoyama T
    Chem Pharm Bull (Tokyo); 1990 Feb; 38(2):510-2. PubMed ID: 2337967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Michaelis-Menten kinetics and the steady-state serum phenytoin/hydroxyphenytoin ratio.
    Bourgeois BF; Wad N
    Ther Drug Monit; 1985; 7(4):405-10. PubMed ID: 4082240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. On the identification of Michaelis-Menten elimination parameters from a single dose-response curve.
    Godfrey KR; Fitch WR
    J Pharmacokinet Biopharm; 1984 Apr; 12(2):193-221. PubMed ID: 6491901
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.